Sexual dysfunction may be common in cancer patients and survivors, but their sexual health is often overlooked.
Intensified ADT with apalutamide, with or without abiraterone plus prednisone, for 52 weeks prolonged PSA progression-free survival compared with ADT alone among men with high-risk biochemically recurrent prostate cancer following radical prostatectomy.
This report reviews the challenges patients with bladder cancer experience related to cystectomy and urinary diversion surgery.
Timely discussions about end-of-life preferences can ensure patients with advanced cancer receive care that aligns with their goals, experts say.
Aggregated data can hide disparities in cancer incidence and outcomes among Asian and Native Hawaiian/Pacific Islander patients in the US.
Data suggest that most patients who use medical aid in dying (MAID) have cancer, but some oncology providers do not feel well informed about MAID.
An oncology nurse at Fox Chase Cancer Center develops a best practice for easing patient discomfort during intravesical therapy for bladder cancer.
This article introduces and reviews emerging artificial intelligence applications in radiation oncology, from diagnostic imaging and interpretation to follow-up patient management.
How the retail giant will use the sensitive medical data it collects is among the concerns.
AML research presented at ASH 2022 highlighted promising combination regimens and suggested that some patients may benefit from less intensive treatment.
Experts outline ways in which health care providers and employers can support cancer patients and caregivers in the workplace.
A review of the benefits of exercise for men with prostate cancer describes exercises and routines that may improve outcomes for this patient population.
Addressing moral distress means not just obtaining ethics consultation as needed but also dealing with the feeling of powerlessness that often accompanies it.
A review of the importance family, friends, and a support system have on the cancer journey and survival outcomes for young adults with cancer.
Prior to the introduction of CAR T-cell therapy, pediatric patients with ALL had limited treatment options for relapsed or refractory disease.